{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:03:40Z","timestamp":1773281020254,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,28]],"date-time":"2018-10-28T00:00:00Z","timestamp":1540684800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s10384-018-0635-0","type":"journal-article","created":{"date-parts":[[2018,10,28]],"date-time":"2018-10-28T02:05:39Z","timestamp":1540692339000},"page":"40-45","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil in Japanese patients with various subtypes of glaucoma"],"prefix":"10.1007","volume":"63","author":[{"given":"Takashi","family":"Komizo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Aihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,28]]},"reference":[{"key":"635_CR1","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S0002-9394(98)00272-4","volume":"126","author":"Collaborative Normal-Tension Glaucoma Study Group","year":"1998","unstructured":"Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1998;126:498\u2013505.","journal-title":"Am J Ophthalmol."},{"key":"635_CR2","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","volume":"120","author":"A Heijl","year":"2002","unstructured":"Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268\u201379.","journal-title":"Arch Ophthalmol."},{"key":"635_CR3","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/archopht.120.6.701","volume":"120","author":"MA Kass","year":"2002","unstructured":"Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701\u201313.","journal-title":"Arch Ophthalmol."},{"key":"635_CR4","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10384-015-0392-2","volume":"59","author":"MS Kook","year":"2015","unstructured":"Kook MS, Simonyi S, Sohn YH, Kim CY, Park KH. Bimatoprost 0.01% for previously treated patients with open-angle glaucoma or ocular hypertension in the Korean clinical setting. Jpn J Ophthalmol. 2015;59:325\u201334.","journal-title":"Jpn J Ophthalmol"},{"key":"635_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s10384-015-0413-1","volume":"60","author":"SY Cho","year":"2016","unstructured":"Cho SY, Kim YY, Yoo C, Lee T. Twenty-four-hour efficacy of preservative-free tafluprost for open-angle glaucoma patients, assessed by home intraocular pressure (Icare-ONE) and blood-pressure monitoring. Jpn J Ophthalmol. 2016;60:27\u201334.","journal-title":"Jpn J Ophthalmol."},{"key":"635_CR6","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s10384-016-0433-5","volume":"60","author":"N Shoji","year":"2016","unstructured":"Shoji N, Kasahara M, Iijima A, Takahashi M, Tatsui S, Matsumura K, et al. Short-term evaluation of trabectome surgery performed on Japanese patients with open-angle glaucoma. Jpn J Ophthalmol. 2016;60:156\u201365.","journal-title":"Jpn J Ophthalmol."},{"key":"635_CR7","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1007\/s10384-016-0468-7","volume":"60","author":"D Tanaka","year":"2016","unstructured":"Tanaka D, Nakanishi H, Hangai M, Akagi T, Morooka S, Ikeda HO, et al. Influence of high myopia on outcomes of trabeculectomy with mitomycin C in patients with primary open-angle glaucoma. Jpn J Ophthalmol. 2016;60:446\u201353.","journal-title":"Jpn J Ophthalmol."},{"key":"635_CR8","doi-asserted-by":"publisher","first-page":"19640","DOI":"10.1038\/srep19640","volume":"6","author":"Y Kaneko","year":"2016","unstructured":"Kaneko Y, Ohta M, Inoue T, Mizuno K, Isobe T, Tanabe S, et al. Effects of K-115 (Ripasudil), a novel ROCK inhibitor, on trabecular meshwork and Schlemm\u2019s canal endothelial cells. Sci Rep. 2016;6:19640.","journal-title":"Sci Rep."},{"key":"635_CR9","first-page":"1317","volume":"9","author":"N Xu","year":"2017","unstructured":"Xu N, Chen SH, Qu GY, Li XD, Lin W, Xue XY, et al. Fasudil inhibits proliferation and collagen synthesis and induces apoptosis of human fibroblasts derived from urethral scar via the Rho\/ROCK signaling pathway. Am J Transl Res. 2017;9:1317\u201325.","journal-title":"Am J Transl Res."},{"key":"635_CR10","doi-asserted-by":"publisher","first-page":"5549","DOI":"10.1167\/iovs.07-0878","volume":"48","author":"M Honjo","year":"2007","unstructured":"Honjo M, Tanihara H, Kameda T, Kawaji T, Yoshimura N, Araie M. Potential role of Rho-associated protein kinase inhibitor Y-27632 in glaucoma filtration surgery. Invest Ophthalmol Vis Sci. 2007;48:5549\u201357.","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"635_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.exer.2016.07.001","volume":"149","author":"A Futakuchi","year":"2016","unstructured":"Futakuchi A, Inoue T, Fujimoto T, Inoue-Mochita M, Kawai M, Tanihara H. The effects of ripasudil (K-115), a Rho kinase inhibitor, on activation of human conjunctival fibroblasts. Exp Eye Res. 2016;149:107\u201315.","journal-title":"Exp Eye Res."},{"key":"635_CR12","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1001\/jamaophthalmol.2015.0525","volume":"133","author":"H Tanihara","year":"2015","unstructured":"Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Suganami H, et al. Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil (K-115) combined with timolol or latanoprost. JAMA Ophthalmol. 2015;133:755\u201361.","journal-title":"JAMA Ophthalmol."},{"key":"635_CR13","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1007\/s12325-016-0389-3","volume":"33","author":"S Sato","year":"2016","unstructured":"Sato S, Hirooka K, Nitta E, Ukegawa K, Tsujikawa A. Additive intraocular pressure lowering effects of the Rho kinase inhibitor, Ripasudil in glaucoma patients not able to obtain adequate control after other maximal tolerated medical therapy. Adv Ther. 2016;33:1628\u201334.","journal-title":"Adv Ther."},{"key":"635_CR14","first-page":"93","volume":"38","author":"K Inoue","year":"2018","unstructured":"Inoue K, Okayama R, Shiokawa M, Ishida K, Tomita G. Efficacy and safety of adding ripasudil to existing treatment regimens for reducing intraocular pressure. Int Ophthalmol. 2018;38:93\u20138.","journal-title":"Int Ophthalmol."},{"key":"635_CR15","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1007\/s00417-017-3727-5","volume":"255","author":"H Inazaki","year":"2017","unstructured":"Inazaki H, Kobayashi S, Anzai Y, Satoh H, Sato S, Inoue M, et al. One-year efficacy of adjunctive use of Ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled with maximum medical therapy. Graefes Arch Clin Exp Ophthalmol. 2017;255:2009\u201315.","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"635_CR16","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s40261-017-0509-0","volume":"37","author":"R Matsumura","year":"2017","unstructured":"Matsumura R, Inoue T, Matsumura A, Tanihara H. Efficacy of ripasudil as a second-line medication in addition to a prostaglandin analog in patients with exfoliation glaucoma: a pilot study. Clin Drug Investig. 2017;37:535\u20139.","journal-title":"Clin Drug Investig."},{"key":"635_CR17","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1111\/aos.12599","volume":"93","author":"H Tanihara","year":"2015","unstructured":"Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Suganami H, et al. Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study. Acta Ophthalmol. 2015;93:e254\u201360.","journal-title":"Acta Ophthalmol."},{"key":"635_CR18","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1111\/aos.12829","volume":"94","author":"H Tanihara","year":"2016","unstructured":"Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Fukushima A, et al. One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension. Acta Ophthalmol. 2016;94:e26\u201334.","journal-title":"Acta Ophthalmol"},{"key":"635_CR19","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/IJG.0000000000000552","volume":"26","author":"H Inazaki","year":"2017","unstructured":"Inazaki H, Kobayashi S, Anzai Y, Satoh H, Sato S, Inoue M, et al. Efficacy of the additional use of ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled under maximum medical therapy. J Glaucoma. 2017;26:96\u2013100.","journal-title":"J Glaucoma."},{"key":"635_CR20","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0161-6420(98)96020-1","volume":"105","author":"GO Naumann","year":"1998","unstructured":"Naumann GO, Schl\u00f6tzer-Schrehardt U, K\u00fcchle M. Pseudoexfoliation syndrome for the comprehensive ophthalmologist: intraocular and systemic manifestations. Ophthalmology. 1998;105:951\u201368.","journal-title":"Ophthalmology."},{"key":"635_CR21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0014-4835(73)90164-4","volume":"17","author":"JW Rohen","year":"1973","unstructured":"Rohen JW, Linn\u00e9r E, Witmer R. Electron microscopic studies on the trabecular meshwork in two cases of corticosteroid-glaucoma. Exp Eye Res. 1973;17:19\u201331.","journal-title":"Exp Eye Res."}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10384-018-0635-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-018-0635-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-018-0635-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T05:21:49Z","timestamp":1605331309000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10384-018-0635-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,28]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["635"],"URL":"https:\/\/doi.org\/10.1007\/s10384-018-0635-0","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,28]]},"assertion":[{"value":"10 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T. Komizo, Lecture fee (Kowa); T. Ono, Lecture fees (Bayer, Kowa, Santen, Senju); A. Yagi, None; K. Miyata, Grant (Novartis, Otsuka, Santen, Senju), Lecture fees (Kowa, Novartis, Otsuka, Pfizer, Santen, Senju); M. Aihara, Grant (Alcon, Pfizer), Consultant fees (Crewt Medical Systems, Glaukos, HOYA, Otsuka, Santen, Senju, WaKamoto), Lecture fees (Abbot, Alcon, Allergan, Crewt Medical Systems, HOYA, JFC Sales Plan, Kowa, Nitten, Otsuka, Pfizer, Santen, Senju, WaKamoto).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}